BDNF/NF-κB Signaling in the Neurobiology of Depression

Title:BDNF/NF-κB Signaling in the Neurobiology of Depression

Volume: 23 Issue: 21

Author(s): Ariel Caviedes, Carlos Lafourcade, Claudio Soto and Ursula Wyneken*

Affiliation:

• Laboratorio de Neurociencias, Facultad de Medicina, Universidad de los Andes; Mons. Alvaro del Portillo 12.455, Las Condes; Santiago,Chile

Keywords: BDNF, NF-κB, mood disorders, neurogenesis, plasticity, anhedonia.

Abstract: Background: Mood disorders, consisting of unipolar and bipolar depression, are complex diseases characterized by depressed mood and anhedonia. These core symptoms are accompanied in a varying manner by anxiety, several neurovegetative symptoms and cognitive impairment. Mood disorders are characterized by decreases in neurogenesis, alteration in synaptic structure and synaptic transmission, all of them regulated by BDNF, a neurotrophin that performs multiple functions in the adult central nervous system. Many evidences show that BDNF is critically decreased in mood disorders and plays an essential role in most anti-depressant treatments. In turn, the transcription factor NF-kB has recently emerged as an important player in the pathophysiology of depression, with roles in neurogenesis, synaptic transmission and plasticity.

Cite this article as:

Caviedes Ariel, Lafourcade Carlos, Soto Claudio and Wyneken Ursula*, BDNF/NF-κB Signaling in the Neurobiology of Depression, Current Pharmaceutical Design 2017; 23 (21) . https://dx.doi.org/10.2174/1381612823666170111141915